ADMS News and Press, Adamas Pharmaceuticals Inc. From 09/11/20

EMERYVILLE, Calif., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, announced today two presentations on GOCOVRI ® (...

EMERYVILLE, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company&#...

Adamas Pharmaceuticals (ADMS) recently reported their Q2 earnings with a substantial beat on both EPS and revenue despite an ongoing pandemic. The market did respond appropriately, with the stock trading up nearly 50% following the press release. Unfortunately, the stock is still down over...

Gainers:  Seres Therapeutics (NASDAQ: MCRB ) +356% . More news on: Seres Therapeutics, Inc., Xtant Medical Holdings, Inc., BiomX Inc., Stocks on the move, , Read more ...

The following slide deck was published by Adamas Pharmaceuticals, Inc. in conjunction with their 2020 Q2 earnings Read more ...

Gainers:  Conduent (NASDAQ: CNDT ) +75% . More news on: Conduent Incorporated, OpGen, Inc., Groupon, Inc., Stocks on the move, , Read more ...

Adamas Pharmaceuticals, Inc. (ADMS) Q2 2020 Earnings Conference Call August 7, 2020 4:30 PM Company Participants Peter Vozzo – Investor Relations Neil McFarlane – Chief Executive Officer Vijay Shreedhar – Chief Commercial Officer Chris Prentiss – Chi...

Adamas Pharma (NASDAQ: ADMS ) : Q2 GAAP EPS of -$0.37 beats by $0.24 . More news on: Adamas Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Second quarter 2020 GOCOVRI® product sales of $18.0 million, a 41% increase over second quarter 2019 Total paid prescriptions grew to 8,150, a 32% increase over second quarter 2019 EMERYVILLE, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS...

EMERYVILLE, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2020 second quarter financial results on Thursday, August 6, 2020, after market close. Subsequently, Adamas’ management team will host a conf...